Court Place Advisors LLC Sells 260 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Court Place Advisors LLC cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 5,850 shares of the medical equipment provider’s stock after selling 260 shares during the period. Court Place Advisors LLC’s holdings in Intuitive Surgical were worth $1,974,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after acquiring an additional 196,316 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Intuitive Surgical by 1.0% during the 1st quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider’s stock worth $1,642,287,000 after purchasing an additional 61,659 shares during the period. Morgan Stanley raised its stake in shares of Intuitive Surgical by 29.9% during the 4th quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock worth $1,556,706,000 after purchasing an additional 1,351,002 shares during the period. Jennison Associates LLC raised its stake in shares of Intuitive Surgical by 6.4% during the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock worth $1,340,205,000 after purchasing an additional 274,692 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Intuitive Surgical by 6.6% during the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after purchasing an additional 232,205 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

NASDAQ:ISRG traded down $4.38 during mid-day trading on Wednesday, reaching $374.17. The stock had a trading volume of 1,625,510 shares, compared to its average volume of 1,635,915. The firm has a 50 day moving average price of $387.90 and a two-hundred day moving average price of $342.17. The stock has a market capitalization of $132.62 billion, a P/E ratio of 75.01, a P/E/G ratio of 5.86 and a beta of 1.36. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.12. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.89 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. Intuitive Surgical’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS. Research analysts forecast that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ISRG shares. Stifel Nicolaus lifted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Citigroup lifted their target price on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Raymond James lifted their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Wells Fargo & Company lifted their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Finally, StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $375.70.

Insider Buying and Selling

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the sale, the vice president now owns 110 shares in the company, valued at $43,677.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Fredrik Widman sold 5,041 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the sale, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock worth $95,927,097 in the last quarter. 0.80% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.